Processed data and statistics

Each sheet contains data and statistics generated for the research. Refer to the table legends bellow.<b>Supplementary Table S1. </b>Core microbiome in gut.<b>Supplementary Table S2. </b>Core microbiome in lung.<b>Supplementary Table S3.</b> Adjacency matrix of gut and lung microbiome in healthy controls.<b>Supplementary Table S4.</b> Adjacency matrix of gut and lung microbiome in patients with TB before treatment.<b>Supplementary Table S5.</b> Adjacency matrix of gut and lung microbiome in patients with TB after treatment.<b>Supplementary Table S6.</b> Node score of gut and lung microbiome in healthy controls.<b>Supplementary Table S7.</b> Node score of gut and lung microbiome in patients with TB before treatment.<b>Supplementary Table S8.</b> Node score of gut and lung microbiome in patients with TB after treatment.<b>Supplementary Table S9. </b>Significant results from differential abundance analysis of gut microbiota between HCs and patients with TB before treatment in the gut. Log fold change (logFC) represents the relative abundance in patients with TB compared to healthy controls. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, and linear discriminant analysis (LDA) scores were calculated using LEfSe.<b>Supplementary Table S10. </b>Significant results from differential abundance analysis of gut microbiota between HCs and patients with TB before treatment in the lung. The logFC represents the log-transformed expression values of patients with TB relative to those of healthy controls (HC). The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.<b>Supplementary Table S11.</b> Significant results from differential abundance analysis of gut microbiota between patients with TB before and after treatment in the gut. The logFC represents the log-transformed expression values of patients with TB after treatment relative to those of patients with TB before treatment. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.<b>Supplementary Table S12. </b>Significant results from differential abundance analysis of gut microbiota between patients with TB before and after treatment in the lung. The logFC represents the log-transformed expression values of patients with TB after treatment relative to those of patients with TB before treatment. The logFC, p-values, and false discovery rates (FDR) were obtained from ANCOM-BC, while the linear discriminant analysis (LDA) scores were derived from LEfSe.<b>Supplementary Tables S13. </b>Taxa clustering results in healthy controls.<b>Supplementary Tables S14. </b>Taxa clustering results in patients with TB before treatment.<b>Supplementary Tables S15. </b>Taxa clustering results in patients with TB after treatment.<br>

本数据集各工作表均包含本研究生成的实验数据与统计结果，请参阅下述表格图例。
**补充表S1**：肠道核心微生物组
**补充表S2**：肺部核心微生物组
**补充表S3**：健康对照者肠道与肺部微生物组邻接矩阵
**补充表S4**：结核病（Tuberculosis, TB）治疗前患者肠道与肺部微生物组邻接矩阵
**补充表S5**：结核病（TB）治疗后患者肠道与肺部微生物组邻接矩阵
**补充表S6**：健康对照者肠道与肺部微生物组节点得分
**补充表S7**：结核病（TB）治疗前患者肠道与肺部微生物组节点得分
**补充表S8**：结核病（TB）治疗后患者肠道与肺部微生物组节点得分
**补充表S9**：健康对照（healthy controls, HC）与结核病（TB）治疗前患者肠道微生物组差异丰度分析的显著结果。对数倍变化（log fold change, logFC）代表结核病患者相较于健康对照者的肠道微生物相对丰度。logFC、P值及错误发现率（false discovery rates, FDR）均通过ANCOM-BC分析得到，线性判别分析（Linear Discriminant Analysis, LDA）得分由LEfSe计算得出。
**补充表S10**：健康对照（HC）与结核病（TB）治疗前患者肠道微生物组肺部差异丰度分析的显著结果。logFC代表结核病患者相较于健康对照者的微生物组表达值的对数转换值。logFC、P值及错误发现率（FDR）均通过ANCOM-BC分析得到，线性判别分析（LDA）得分由LEfSe计算得出。
**补充表S11**：结核病（TB）治疗前后患者肠道微生物组差异丰度分析的显著结果。logFC代表结核病患者治疗后相较于治疗前的微生物组表达值的对数转换值。logFC、P值及错误发现率（FDR）均通过ANCOM-BC分析得到，线性判别分析（LDA）得分由LEfSe计算得出。
**补充表S12**：结核病（TB）治疗前后患者肠道微生物组肺部差异丰度分析的显著结果。logFC代表结核病患者治疗后相较于治疗前的微生物组表达值的对数转换值。logFC、P值及错误发现率（FDR）均通过ANCOM-BC分析得到，线性判别分析（LDA）得分由LEfSe计算得出。
**补充表S13**：健康对照者微生物类群聚类结果
**补充表S14**：结核病（TB）治疗前患者微生物类群聚类结果
**补充表S15**：结核病（TB）治疗后患者微生物类群聚类结果